Hugo Cortés Martínez
Research Subjects
Research Interests
Hugo Cortés Martínez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Solis-Cruz
Nanotechnology Engineering Division, Polytechnic University of the Valley of Mexico, Tultitlan 54910, Mexico
1 shared publication - Carla Olbia Contreras-Ochoa
Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Av. Universidad no. 655, Santa María Ahuacatitlán, Cuernavaca 62100, Morelos, Mexico
1 shared publication - Daniel Hernandez-Patlan
Laboratory 5: LEDEFAR, Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico
1 shared publication - Elvia Adriana Morales Hipólito
Laboratory 5: Laboratorio de Ensayos de Desarrollo Farmacéutico (LEDEFAR), Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico
1 shared publication - Jesús Javier Espinosa-Aguirre
Institute of Biomedical Research, Third Exterior Circuit, National Autonomous University of Mexico. , University City, Mexico City, Mexico
1 shared publication - Mariana Dolores-Hernández
Laboratory 5: Pharmaceutical Development Testing Laboratory (LEDEFAR), Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico
1 shared publication
Latest Publications
- Open Access
- 11 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 983
Development and In Vitro Cytotoxicity Evaluation of Individual and Combined Injectable Solutions of Curcumin and Resveratrol Against Lung Cancer Cells
The objective of the present study was to develop injectable solutions of curcumin (CUR) and resveratrol (RES) for intravenous administration as a strategy to increase their solubility and stability, as well as to evaluate their cytotoxic potential, individually and in combination, on human lung non-small adenocarcinoma cells (A549 cells) and non-tumoral cells isolated from normal human bronchial epithelium (BEAS cells) to establish possible synergistic effects and potential therapeutic alternatives for lung cancer. Using factorial experimental designs, the components of the injectable CUR and RES solutions were selected, and their hemolytic potential was evaluated by a static method. In addition, combinations of injectable CUR:RES solutions (25:75, 50:50 and 75:25) were prepared from the individual ones, and their stability under refrigeration conditions and cytotoxic potential on A549 and BEAS cells were evaluated. The stability of the injectable solutions of CUR, RES and their different combinations was maintained for 3 months, except for the 25:75 combination of CUR:RES. Furthermore, the cytotoxic potential of CUR and RES on tumoral cells (A549) and non-tumoral (BEAS) cells was evaluated, indicating a dose-dependent effect; the combination of CUR:RES 50:50 and the combination of CUR:RES 75:25 presented synergistic effects in reducing cell viability. This study suggests that injectable solutions of CUR, RES and their combination for intravenous administration could be potential viable candidates and should be evaluated for their efficacy in animal models of lung cancer to establish new possible treatments.
- 11 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 983
Open AccessDevelopment and In Vitro Cytotoxicity Evaluation of Individual and Combined Injectable Solutions of Curcumin and Resveratrol Against Lung Cancer Cells
The objective of the present study was to develop injectable solutions of curcumin (CUR) and resveratrol (RES) for intravenous administration as a strategy to increase their solubility and stability, as well as to evaluate their cytotoxic potential, individually and in combination, on human lung non-small adenocarcinoma cells (A549 cells) and non-tumoral cells isolated from normal human bronchial epithelium (BEAS cells) to establish possible synergistic effects and potential therapeutic alternatives for lung cancer. Using factorial experimental designs, the components of the injectable CUR and RES solutions were selected, and their hemolytic potential was evaluated by a static method. In addition, combinations of injectable CUR:RES solutions (25:75, 50:50 and 75:25) were prepared from the individual ones, and their stability under refrigeration conditions and cytotoxic potential on A549 and BEAS cells were evaluated. The stability of the injectable solutions of CUR, RES and their different combinations was maintained for 3 months, except for the 25:75 combination of CUR:RES. Furthermore, the cytotoxic potential of CUR and RES on tumoral cells (A549) and non-tumoral (BEAS) cells was evaluated, indicating a dose-dependent effect; the combination of CUR:RES 50:50 and the combination of CUR:RES 75:25 presented synergistic effects in reducing cell viability. This study suggests that injectable solutions of CUR, RES and their combination for intravenous administration could be potential viable candidates and should be evaluated for their efficacy in animal models of lung cancer to establish new possible treatments.